|本期目录/Table of Contents|

[1]周诚忠,闻炳基,夏炎春,等.三维适形放疗联合奥沙利铂化疗治疗肝转移癌的临床观察[J].医学研究与战创伤救治(原医学研究生学报),2011,13(01):45-47.
 ZHOU Cheng-zhong,WEN Bing-ji,XIA Yan-chun,et al.Effects of three-dimensional conformal radiotherapy combined with oxaliplatin on patients with liver metastases cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2011,13(01):45-47.
点击复制

三维适形放疗联合奥沙利铂化疗治疗肝转移癌的临床观察()

《医学研究与战创伤救治》(原医学研究生学报)[ISSN:1672-271X/CN:32-1713/R]

卷:
第13卷
期数:
2011年01期
页码:
45-47
栏目:
出版日期:
2011-01-20

文章信息/Info

Title:
Effects of three-dimensional conformal radiotherapy combined with oxaliplatin on patients with liver metastases cancer
文章编号:
1672-271X(2011)01-0045-03
作者:
周诚忠闻炳基夏炎春夏海波张力彬
315040 浙江宁波,解放军113医院放疗科
Author(s):
ZHOU Cheng-zhong WEN Bing-ji XIA Yan-chun XIA Hai-bao ZHANG Li-bin
Department of Radiotherapy, 113 Hospital of PLA, Ningbo 315040,Zhejiang,China
关键词:
肝脏肿瘤 三维适形放疗 奥沙利铂
Keywords:
liver cancer three-dimensional conformal radiotherapy oxaliplatin
分类号:
R735.7
DOI:
-
文献标志码:
A
摘要:
目的 分析三维适形放疗(three-dimensional conformal radiotherapy 3-DCRT)联合奥沙利铂化疗治疗肝转移癌的临床疗效。方法 30例肝转移癌静脉滴入奥沙利铂130 mg/m2,第1天静脉滴入;5-氟尿嘧啶300 mg/m2和亚叶酸钙200 mg/m2 第1~5天静脉滴入,间隔3周重复,共2个疗程。同步进行三维适形放疗,设4~6个弧形或非共面适形固定野照射,参考剂量曲线选定为80%。放疗处方剂量45~55 Gy,中位剂量50 Gy,3~4 Gy /次,3 次 /周。结果 治疗后3~6个月内复查增强CT或MRI,30例中,3例完全缓解(CR),16例部分缓解(PR),7例无变化(NC),4例恶化(PD),总有效率(CR+PR)为63.3%,肿瘤局部控制率为78.5%,中位生存期15个月,1、2、3年生存率分别为65.3%、31.1%和 10.6%,全组无严重并发症发生。结论 三维适形放疗联合奥沙利铂治疗肝转移癌能提高肿瘤局部照射剂量和增加肿瘤局部控制率,是一种安全、有效的治疗手段。
Abstract:
Objective To observe the clinical efficacy of three-dimensional conformal radiotherapy (3-DCRT) combined with oxaliplatin (L-OHP) on patients with liver metastases cancer. Methods 30 patients with liver metastases cancer received L-OHP 130 mg/m2, D1 iv drip. 5-FU 300 mg/m2 and CF 200 mg/m2 with iv drip on D1-5 was given in two cycles (Twenty-one days as one cycle). 30 patients received 3-DCRT (45-55 Gy/8-12f, 3-4 Gy/f, 3f/w, prescribed at the 80% isodose). Results CT or MRI were performed 3-6 months after radiotherapy. 3 patients were CR, 16 were PR, 7 were NC and 4 were PD. The overall response rate (CR+PR) was 63.3%. The 1-, 2-, and 3-year survival rates were 65%, 31% and 10% respectively. The median survival duration was 15.0 months. No serious complication was observed in the course. Conclusion 3DCRT combined with oxaliplatinL-OHP, 5-FU and CF is an effective and safe treatment modality for liver metastases cancer. It can improve life quality and prolonging survival time of patients as well.

参考文献/References:

[1]闫 东,李 槐,魏文强,等.经肝动脉介入治疗肝转移癌的疗效分析[J].中华消化外科杂志,2009,8(2):107-109.
[2]张宗明.中晚期肝癌治疗方法的选择[J].中国现代普通外科进展, 2008,11(1):4-6.
[3]孙 燕,石远凯.临床肿瘤内科手册[M].5版.北京:人民卫生出版社,2009:526-527.
[4]罗 政,饶 建,殷蔚伯,等.放疗在原发性肝癌治疗中地位和现状[J].中华放射肿瘤学杂志,2006,15(4):345-346.
[5]梁 军,冯勤付,张 可,等.三维适形放疗与常规放疗剂量学优势的比较[J].临床肿瘤学杂志,2006,11(11):814-817.
[6]殷蔚伯,谷铣之,刘泰福,等.肿瘤放射治疗学[M].4版.北京:北京医科大学中国协和医科大学联合出版社,2008:153-156.
[7]周陈华,陈华津,王晓云,等.中晚期肝癌三维适形放疗的临床观察[J].中华放肿瘤学杂志,2005,14(2):129-130.
[8]周文丽,考 军,于长青,等.奥沙利铂联合亚叶酸钙和5-氟尿嘧啶治疗晚期肝转移癌30例近期疗效观察 [J].肿瘤防治杂志,2005,12(5):399.

相似文献/References:

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2011-01-20